ArticleRSC advances2025
Development of advanced drug-loaded graphene quantum dots with improved photoluminescence properties for enhanced targeted therapy and nano-imaging technologies.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, a new system of drug-functionalized graphene quantum dots (GQDs) is presented for combined therapeutic delivery and imaging. To do this, doxorubicin (DOX), which is a strong anticancer reagent, is chosen due to its organic nature. Additionally, to investigate quantum confinement effects on the system's efficiency, diamond-shaped GQDs with two different sizes are utilized. We theoretically investigate the optoelectronic and photoluminescence behavior of various drug-GQD arrangements, to evaluate their nanomedical diagnostic efficiency. The findings confirm the accuracy of the systems investigated. The stability of the hybrid structures is confirmed by the absence of imaginary frequencies. As the size of GQD increases, the HOMO-LUMO gap energy decreases under the regulation of drug binding and nanoparticles hardness. This size-dependent effect also causes a red-shift in the optical emission and absorption spectra upon DOX conjugation. Furthermore, DOX-conjugated GQDs exhibit strong near-infrared photoluminescence, suggesting their application potential in drug delivery and diagnostics in nanomedicine.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.